Metabolic Function for Human Renalase: Oxidation of Isomeric Forms of β-NAD(P)H that Are Inhibitory to Primary Metabolism

被引:48
|
作者
Beaupre, Brett A. [1 ]
Hoag, Matt R. [1 ]
Roman, Joseph [1 ]
Foersterling, F. Holger [1 ]
Moran, Graham R. [1 ]
机构
[1] Univ Wisconsin, Dept Chem & Biochem, Milwaukee, WI 53211 USA
基金
美国国家科学基金会;
关键词
NICOTINAMIDE ADENINE-DINUCLEOTIDE; LACTATE-DEHYDROGENASE INHIBITOR; HEMODIALYSIS-PATIENTS; NADH PREPARATIONS; BLOOD-PRESSURE; ALPHA-NADPH; DPN; PURIFICATION; HYPERTENSION; REDUCTION;
D O I
10.1021/bi5013436
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Renalase is a recently identified flavoprotein that has been associated with numerous physiological maladies. There remains a prevailing belief that renalase functions as a hormone, imparting an influence on vascular tone and heart rate by oxidizing circulating catecholamines, chiefly epinephrine. This activity, however, has not been convincingly demonstrated in vitro, nor has the stoichiometry of this transformation been shown. In prior work we demonstrated that renalase induced rapid oxidation of low-level contaminants of beta-NAD(P)H solutions (Beaupre, B. A. et al. (2013) Biochemistry52, 8929-8937; Beaupre, B. A. et al. (2013) J. Am. Chem. Soc. 135, 13980-13987). Slow aqueous speciation of beta-NAD(P)H resulted in the production of renalase substrate molecules whose spectrophotometric characteristics and equilibrium fractional accumulation closely matched those reported for a-anomers of NAD(P)H. The fleeting nature of these substrates precluded structural assignment. Here we structurally assign and identify two substrates for renalase. These molecules are 2- and 6-dihydroNAD(P), isomeric forms of beta-NAD(P)H that arise either by nonspecific reduction of beta-NAD(P)(+) or by tautomerization of beta-NAD(P)H (4-dihydroNAD(P)). The pure preparations of these molecules induce rapid reduction of the renalase flavin cofactor (230 s(-1) for 6-dihydroNAD, 850 s(-1) for 2-dihydroNAD) but bind only a few fold more tightly than beta-NADH. We also show that 2- and 6-dihydroNAD(P) are potent inhibitors of primary metabolism dehydrogenases and therefore conclude that the metabolic function of renalase is to oxidize these isomeric NAD(P)H molecules to beta-NAD(P)(+), eliminating the threat they pose to normal respiratory activity.
引用
收藏
页码:795 / 806
页数:12
相关论文
共 31 条
  • [21] CHARACTERIZATION OF RAT AND HUMAN-LIVER MICROSOMAL CYTOCHROME-P-450 FORMS INVOLVED IN NIFEDIPINE OXIDATION, A PROTOTYPE FOR GENETIC-POLYMORPHISM IN OXIDATIVE DRUG-METABOLISM
    GUENGERICH, FP
    MARTIN, MV
    BEAUNE, PH
    KREMERS, P
    WOLFF, T
    WAXMAN, DJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1986, 261 (11) : 5051 - 5060
  • [22] METABOLISM OF DIAZIQUONE BY NAD(P)H-(QUINONE ACCEPTOR) OXIDOREDUCTASE (DT-DIAPHORASE) - ROLE IN DIAZIQUONE-INDUCED DNA DAMAGE AND CYTOTOXICITY IN HUMAN COLON-CARCINOMA CELLS
    SIEGEL, D
    GIBSON, NW
    PREUSCH, PC
    ROSS, D
    CANCER RESEARCH, 1990, 50 (22) : 7293 - 7300
  • [23] Dynamic NAD(P)H post-synaptic autofluorescence signals for the assessment of mitochondrial function in a neurodegenerative disease: Monitoring the primary motor cortex of G93A mice, an amyotrophic lateral sclerosis model
    Loizzo, Stefano
    Pieri, Massimo
    Ferri, Alberto
    Carri, Maria Teresa
    Zona, Cristina
    Fortuna, Andrea
    Vella, Stefano
    MITOCHONDRION, 2010, 10 (02) : 108 - 114
  • [24] Beas2B cells as a model of polycyclic aromatic hydrocarbon metabolism in noncancerous human lung: Metabolic consequences of [3H]-B[a]P and [3H]-B[a]P-7,8-dihydrodiol treatment
    Kushman, Mary E.
    Gelhaus, Stacy L.
    Penning, Trevor M.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [25] NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells
    Singh, Seema
    Zahid, Muhammad
    Saeed, Muhammad
    Gaikwad, Nilesh W.
    Meza, Jane L.
    Cavalieri, Ercole L.
    Rogan, Eleanor G.
    Chakravarti, Dhrubajyoti
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2009, 117 (1-3): : 56 - 66
  • [26] Inhibitory and inductive effects of 4- or 5-methyl-2-mercaptobenzimida-zole, thyrotoxic and hepatotoxic rubber antioxidants, on several forms of cytochrome P450 in primary cultured rat and human hepatocytes
    Miyajima, Atsuko
    Kuroda, Yukie
    Sakemi-Hoshikawa, Kazue
    Usami, Makoto
    Mitsunaga, Katsuyoshi
    Irie, Tomohiko
    Ohno, Yasuo
    Sunouchi, Momoko
    TOXICOLOGY REPORTS, 2020, 7 : 979 - 985
  • [27] Effect of Ang II on the generation of superoxide anion via NAD(P)H oxidase enzyme complex in primary cultured vascular smooth muscle cells isolated from spontaneously hypertensive and normotensive rat aortas, and role of Src in this metabolic pathway
    Uzuner, F.
    Tokay, A.
    Cetin, A.
    Yesilkaya, A.
    FEBS JOURNAL, 2010, 277 : 131 - 131
  • [28] Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1):: NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells
    Reigan, Philip
    Colucci, Marie A.
    Siegel, David
    Chilloux, Aurelie
    Moody, Christopher J.
    Ross, David
    BIOCHEMISTRY, 2007, 46 (20) : 5941 - 5950
  • [29] Induction of heme oxygenase-1 (HO-1) and NAD[P]H:: Quinone oxidoreductase 1 (NQO1) by a phenolic antioxidant, butylated hydroxyanisole (BHA) and its metabolite, tert-butylhydroquinone (tBHQ) in primary-cultured human and rat hepatocytes
    Keum, Young-Sam
    Han, Yong-Hae
    Liew, Celine
    Kim, Jung-Hwan
    Xu, Changjiang
    Yuan, Xiaoling
    Shakarjian, Michael P.
    Chong, Saeho
    Kong, Ah-Ng
    PHARMACEUTICAL RESEARCH, 2006, 23 (11) : 2586 - 2594
  • [30] Induction of Heme Oxygenase-1 (HO-1) and NAD[P]H: Quinone Oxidoreductase 1 (NQO1) by a Phenolic Antioxidant, Butylated Hydroxyanisole (BHA) and Its Metabolite, tert-Butylhydroquinone (tBHQ) in Primary-Cultured Human and Rat Hepatocytes
    Young-Sam Keum
    Yong-Hae Han
    Celine Liew
    Jung-Hwan Kim
    Changjiang Xu
    Xiaoling Yuan
    Michael P. Shakarjian
    Saeho Chong
    Ah-Ng Kong
    Pharmaceutical Research, 2006, 23 : 2586 - 2594